IOVA
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. insider trading
Iovance Biotherapeutics, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in San Carlos, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent IOVA insider transactions
Iovance Biotherapeutics, Inc.'s insiders made no open-market purchases or sales in the company's most recent Form 4 filings — those filings are share grants, option exercises and dispositions back to the issuer, which are compensation rather than decisions. That absence is itself worth knowing: nobody at IOVA spent or raised their own money in the market over this stretch. Two years of open-market trades are below.
SEC Form 4 data, Q3 2024 to Q2 2026
IOVA insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 4 insiders traded IOVA on the open market: 3 purchases worth $107.2K and 1 sale worth $503K. In the last four quarters alone: no open-market trades at all.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | — | |
| Q2 2025 | +$107.2K3 buys | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | −$503K1 sale | |
| Q3 2024 | — | — |
- Largest purchase
- +$55.2K of IOVA by Kirby Daniel Gordon (Chief Commercial Officer) on Jun 05, 2025.
- Largest sale
- −$503K of IOVA by Maynard Ryan D (Director) on Nov 12, 2024.
Open-market transactions through Jun 30, 2026most recent first
Kirby Daniel Gordon
Chief Commercial Officer
+$55.2K
Jun 05, 2025
30,000 sh · $1.84
Puri Raj K.
Chief Regulatory Officer
+$9.7K
May 23, 2025
5,600 sh · $1.74
Vogt Frederick G
Interim CEO & General Counsel · Director
+$42.3K
May 14, 2025
25,000 sh · $1.69
Maynard Ryan D
Director
−$503K
Nov 12, 2024
50,000 sh · $10.06
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jun 05, 2025 | Kirby Daniel GordonChief Commercial Officer | 30,000 | $1.84 | +$55.2K |
| May 23, 2025 | Puri Raj K.Chief Regulatory Officer | 5,600 | $1.74 | +$9.7K |
| May 14, 2025 | Vogt Frederick GInterim CEO & General Counsel · Director | 25,000 | $1.69 | +$42.3K |
| Nov 12, 2024 | Maynard Ryan DDirector | 50,000 | $10.06 | −$503K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Iovance Biotherapeutics, Inc. company record
- SEC industry classification
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Carlos, CA
- Incorporated in
- DE
- Listed on
- Nasdaq
- SEC Central Index Key
- 0001425205
- Previously filed as
- Lion Biotechnologies, Inc.
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought IOVA
What the stock actually did in the 90 days following each open-market purchase
Don't check IOVA — let it ping you
Get told the moment an insider moves on IOVA
Pro watches Iovance Biotherapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add IOVA to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read IOVA insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Have IOVA insiders bought or sold stock recently?
- No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders appear in the Form 4 filings scanned for this page. Grants, option exercises and tax withholding are not counted as trades.
- How much IOVA stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 4 Iovance Biotherapeutics, Inc. insiders made 3 open-market purchases worth $107.2K and 1 sale worth $503K. In the four quarters to Jun 30, 2026: no purchases and no sales. The largest purchase was Kirby Daniel Gordon buying $55.2K on Jun 05, 2025. The largest sale was Maynard Ryan D selling $503K on Nov 12, 2024.
- When did an insider last buy IOVA shares?
- The most recent open-market purchase in SEC's data through Jun 30, 2026 is Kirby Daniel Gordon (Chief Commercial Officer) buying $55.2K on Jun 05, 2025.
- Where does IOVA insider trading data come from?
- From the Form 4 filings Iovance Biotherapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.